Boehringer Ingelheim Biopharmaceuticals China achieves carbon neutrality certification Go back »

2024-08-15 | All chapters

Boehringer Ingelheim China biopharmaceutical production and supply site in Zhangjiang, Shanghai, has officially achieved carbon neutrality. This milestone has been certified by both the Shanghai Environment and Energy Exchange and TÜV Rheinland in Germany, marking it one of the first carbon-neutral biopharmaceutical CDMO companies worldwide.

As the first leading biopharmaceutical manufacturing site in China by a multinational company, BioChina has been actively driving the implementation of sustainable development strategy since its establishment in 2015. Its two plants, designed and constructed applying sustainable principles, achieved peak carbon emissions in 2021 (12,196 tons). Since then, Boehringer has developed a comprehensive carbon neutrality roadmap, which involves a variety of decarbonization initiatives, including upgrades of energy efficiency, conversion to renewable energy, optimization of manufacturing, warehousing, and laboratory processes, leading to the neutralization of carbon emissions today.

Source: Boehringer Ingelheim